Pezzarossa A, Cimicchi M C, Orlandi N, Gnudi A, Manca C, Perrone A, Bolognesi R
Chair of Endocrinology, University of Parma, Italy.
Cardiovasc Drugs Ther. 1988 Dec;2(5):669-72. doi: 10.1007/BF00054207.
The metabolic effects of calcium channels blockers have already been studied both in normal and diabetic humans and results were quite controversial, depending on the drug used, the dose administered, and the type of patient. Little information exists on the use of Ca2+ antagonists in obese people, even if these persons are a population risk group for developing diseases in which these drugs may be requested for treatment. Thus, we evaluated, in obese humans, the metabolic effects of two Ca2+ antagonist drugs recently made commercially available to treat diseases such as hypertension and ischemic heart disease: nicardipine and diltiazem. Sixteen obese subjects were submitted to an intravenous glucose tolerance test (0.33 g/kg) (IVGTT) and an arginine test tolerance (30 g in 30 minutes) (ATT) before and after a week of oral treatment with nicardipine (60 mg/day) or diltiazem (360 mg/day). Plasma values of glucose, insulin, and C-peptide during IVGTT, and of glucose, insulin and glucagon during ATT did not show any modification during treatment with either drug. Thus the Ca2+ antagonists, nicardipine and diltiazem, at therapeutic doses in obese subjects do not significantly affect glucose tolerance or insulin and glucagon release.
钙通道阻滞剂的代谢作用已在正常人和糖尿病患者中进行过研究，结果颇具争议，这取决于所使用的药物、给药剂量以及患者类型。关于肥胖人群使用钙离子拮抗剂的信息很少，即便这些人是罹患某些疾病的高危人群，而在治疗这些疾病时可能会用到这些药物。因此，我们评估了两种最近已上市用于治疗高血压和缺血性心脏病等疾病的钙离子拮抗剂药物——尼卡地平和地尔硫䓬——对肥胖人群的代谢作用。16名肥胖受试者在接受尼卡地平（60毫克/天）或地尔硫䓬（360毫克/天）口服治疗一周前后，分别接受了静脉葡萄糖耐量试验（0.33克/千克）（IVGTT）和精氨酸耐量试验（30分钟内给予30克）（ATT）。IVGTT期间的血浆葡萄糖、胰岛素和C肽值，以及ATT期间的血浆葡萄糖、胰岛素和胰高血糖素值在使用这两种药物治疗期间均未显示出任何变化。因此，在肥胖受试者中，治疗剂量的钙离子拮抗剂尼卡地平和地尔硫䓬不会显著影响葡萄糖耐量或胰岛素及胰高血糖素的释放。
